HTA80 Cost-Effectiveness of Ocrelizumab Compared with Dmt for the Treatment of Relapsing-Remitting Multiple Sclerosis in Czech Republic
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.1509
https://www.valueinhealthjournal.com/article/S1098-3015(23)01609-1/fulltext
Title :
HTA80 Cost-Effectiveness of Ocrelizumab Compared with Dmt for the Treatment of Relapsing-Remitting Multiple Sclerosis in Czech Republic
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01609-1&doi=10.1016/j.jval.2023.03.1509
First page :
Section Title :
Open access? :
No
Section Order :
10910